ANCA Vasculitis News

September 15, 2021September 15, 2021

Tofacitinib Seen as Effective and Safe for AAV Patients in Pilot Study

ANCA Vasculitis News

Treatment with tofacitinib is well tolerated and effectively induces remission in people with ANCA-associated vasculitis (AAV), while enabling patients to lower their glucocorticoid doses, a small pilot study suggests. These results ... Read more

September 13, 2021September 13, 2021

New Institute Aims to Leave No Rare Disease Patient Behind

ANCA Vasculitis News

A newly launched non-profit institute is seeking to advance research, and the development of new therapies, for people with rare diseases — a patient community with some of the largest ... Read more

September 10, 2021September 10, 2021

Group Focuses on Rare Disease Clinical Trial Participation

ANCA Vasculitis News

Participation in clinical trials exposes rare disease patients to financial, physical, and emotional pressures, according to the results of a patient focus group series. “Rare disease trial participants are running ... Read more

September 8, 2021September 8, 2021

Lower Dose Nucala Safe, Effective in EGPA With Fewer Adverse Events

ANCA Vasculitis News

A lower, 100 mg dose of Nucala (mepolizumab) is equally effective at treating eosinophilic granulomatosis with polyangiitis (EGPA) as the standard 300 mg dose, and leads to less frequent adverse ... Read more

September 1, 2021September 1, 2021

1st-course Rituximab Found to Not Trigger Antibodies in AAV Patients

ANCA Vasculitis News

A first course of rituximab is sufficient to trigger the development of anti-rituximab antibodies in patients with systemic lupus erythematosus (SLE) but not in those with ANCA-associated vasculitis (AAV), a ... Read more

August 30, 2021August 31, 2021

‘Running for Rare’: NORD a Charity Partner of 2021 NYC Marathon

ANCA Vasculitis News

The National Organization for Rare Disorders, known as NORD, was named an official charity partner of the 2021 TCS New York City Marathon, which will be held Nov. 7 both ... Read more

August 25, 2021August 25, 2021

Using Rituximab Long-term May Cause Inflammatory Vaginitis

ANCA Vasculitis News, COVID-19 News

Inflammatory vaginitis — inflammation of the vagina — may develop in women receiving long-term treatment with rituximab for ANCA-associated vasculitis (AAV) or other autoimmune diseases, a U.S. study says. The ... Read more

August 23, 2021August 23, 2021

‘Not Alone in the Dark’: New Guide for, by Caregivers of Children With Rare Diseases

ANCA Vasculitis News

The National Alliance for Caregiving, in partnership with Global Genes, has issued a free guidebook, available online, that offers resources and support for caregivers of children with rare diseases. “The ... Read more

August 18, 2021August 18, 2021

Mycophenolate Mofetil Can Effectively Induce Remission in EGPA

ANCA Vasculitis News

Mycophenolate mofetil (MMF) is well-tolerated and can be used to induce remission in people with eosinophilic granulomatosis with polyangiitis (EGPA), a type of ANCA-associated vasculitis (AAV), a real-world study shows. ... Read more

August 16, 2021August 16, 2021

Register Now for Global Genes’ RARE Patient Advocacy Summit

ANCA Vasculitis News

Registration is now open for Global Genes‘ 2021 RARE Patient Advocacy Summit. This year’s hybrid event will be livestreamed from California Sept. 27-29, and some seats also are available for attending ... Read more

August 11, 2021August 11, 2021

NORD Rare Disease Summit, Online Oct. 18-19, Open for Registration

ANCA Vasculitis News, COVID-19 News

Registration is now open for the 2021 Rare Diseases and Orphan Products Breakthrough Summit, which will be held virtually Oct. 18–19. The event, also known as the National Organization for ... Read more

August 9, 2021August 9, 2021

New Index May Better Predict All-cause Mortality at AAV Diagnosis

ANCA Vasculitis News

A novel index that computes five simple laboratory results at the time of diagnosis may improve predictions of all-cause mortality among patients with ANCA-associated vasculitis (AAV), a South Korean study ... Read more

August 4, 2021August 4, 2021

Advocates Lobby US Congress During Virtual Rare Disease Week

ANCA Vasculitis News, COVID-19 News

More than 600 people participated in the 10th annual Rare Disease Week on Capitol Hill 2021, held virtually July 14–22, to advocate for the rare disease community. Hosted by the ... Read more

August 4, 2021August 4, 2021

Rituximab Found to Be Safe, Effective for 2 AAV Types in Children

ANCA Vasculitis News

Rituximab is safe and effective for inducing remission in two types of ANCA-associated vasculitis in children and adolescents: granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to data from ... Read more

August 2, 2021August 2, 2021

Low-dose Rituximab May Be Effective in Preventing Relapses

ANCA Vasculitis News

A reduced dosage of rituximab maintenance therapy may be effective at preventing relapses among people with ANCA-associated vasculitis (AAV), a new study reports. Specifically, the researchers said 500 mg infusions ... Read more